Evidence map›Paper›PMID 26801409›Full record

ArticleBMC pulmonary medicine2016

Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.

E L Crawford, A Levin, F Safi, M Lu, A Baugh, X Zhang, J Yeo, S A Khuder, A M Boulos, P Nana-Sinkam and 9 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01130285 (Validation of a Multi-gene Test for Lung Cancer Risk), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01130285 active not recruitingnot on this map

Validation of a Multi-gene Test for Lung Cancer Risk

TypeobservationalSponsorUniversity of Toledo Health Science CampusRan2011 to 2026Enrolled403ConditionsLung CancerArmsLung Cancer Risk Test
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

E L CrawfordDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
A LevinDepartment of Biostatistics, Henry Ford Hospital System, Detroit, MI, USA.
F SafiDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
M LuDepartment of Biostatistics, Henry Ford Hospital System, Detroit, MI, USA.
A BaughDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
X ZhangDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
J YeoDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
S A KhuderDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
A M BoulosDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA.
P Nana-SinkamOhio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, OH, USA.
P P MassionThoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
D A ArenbergUniversity of Michigan, Ann Arbor, MI, USA.
D MidthunMayo Clinic, Rochester, MN, USA.
P J MazzoneCleveland Clinic, Cleveland, OH, USA.
S D NathanInova Fairfax Hospital, Falls Church, VA, USA.
R WainzThe Toledo Hospital, Toledo, OH, USA.
G SilvestriMedical University of South Carolina, Charleston, SC, USA.
J TitaMercy/St. Vincent's Hospital, Toledo, OH, USA.
J C WilleyDepartment of Pulmonary and Critical Care, The University of Toledo Medical Center, Toledo, OH, USA. james.willey2@utoledo.edu.
University of Toledo Medical Center · USHenry Ford Hospital · USCleveland Clinic · USInova Fairfax Hospital · USMayo Clinic in Arizona · USMedical University of South Carolina · USMercy St. Vincent Medical Center · USProMedica Toledo Hospital · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of Michigan · USVanderbilt University · US

Funding

Inherited genetic risk factors common to COPD and lung cancer.R01HL108016 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI WILLEY, JAMES C. · 2011 to 2014
$1.9M
Validation of a multi-gene test for lung cancer riskRC2CA148572 · NCI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI WILLEY, JAMES C. · 2009 to 2010
$1.6M
NCI NIH HHS CA148572NCI NIH HHS RC2 CA148572NHLBI NIH HHS HL108016NHLBI NIH HHS R01 HL108016
6 · The paper itself

Abstract

backgroundThe Lung Cancer Risk Test (LCRT) trial is a prospective cohort study comparing lung cancer incidence among persons with a positive or negative value for the LCRT, a 15 gene test measured in normal bronchial epithelial cells (NBEC). The purpose of this article is to describe the study design, primary endpoint, and safety; baseline characteristics of enrolled individuals; and establishment of a bio-specimen repository. METHODS/

designEligible participants were aged 50-90 years, current or former smokers with 20 pack-years or more cigarette smoking history, free of lung cancer, and willing to undergo bronchoscopic brush biopsy for NBEC sample collection. NBEC, peripheral blood samples, baseline CT, and medical and demographic data were collected from each subject. DISCUSSION: Over a two-year span (2010-2012), 403 subjects were enrolled at 12 sites. At baseline 384 subjects remained in study and mean age and smoking history were 62.9 years and 50.4 pack-years respectively, with 34% current smokers. Obstructive lung disease (FEV1/FVC <0.7) was present in 157 (54%). No severe adverse events were associated with bronchoscopic brushing. An NBEC and matched peripheral blood bio-specimen repository was established. The demographic composition of the enrolled group is representative of the population for which the LCRT is intended. Specifically, based on baseline population characteristics we expect lung cancer incidence in this cohort to be representative of the population eligible for low-dose Computed Tomography (LDCT) lung cancer screening. Collection of NBEC by bronchial brush biopsy/bronchoscopy was safe and well-tolerated in this population. These findings support the feasibility of testing LCRT clinical utility in this prospective study. If validated, the LCRT has the potential to significantly narrow the population of individuals requiring annual low-dose helical CT screening for early detection of lung cancer and delay the onset of screening for individuals with results indicating low lung cancer risk. For these individuals, the small risk incurred by undergoing once in a lifetime bronchoscopic sample collection for LCRT may be offset by a reduction in their CT-related risks. The LCRT biospecimen repository will enable additional studies of genetic basis for COPD and/or lung cancer risk.

trial registrationThe LCRT Study, NCT 01130285, was registered with Clinicaltrials.gov on May 24, 2010.

Indexed as

AgedAged, 80 and overAgricultureAsbestosBiological Specimen BanksBronchiBronchoscopyCohort StudiesEarly Detection of CancerEpithelial CellsFemaleForced Expiratory VolumeGenetic Predisposition to DiseaseHumansIncidenceLung Diseases, ObstructiveAsbestos

Identifiers

PMID26801409
PMCPMC4722707
OpenAlexW2289210241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.